Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Applied Materials

Intel

PPG Industries

Taiwan Semiconductor Manufacturing

Veeco Instruments

The best nanotech stocks to buy belong to companies working on cutting-edge applications and are strong candidates for future growth. The post 7 Best Nanotech Stocks to Buy Now appeared first on InvestorPlace.

7 Best Nanotech Stocks to Buy Now

Ball

Chipotle

Costco

Microsoft

Texas Instruments

Waste Management

The best ESG stocks can help you make money and make the world a better place all at the same time. Here are seven of the best.

7 Best ESG Stocks to Buy Now

Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Thermo Fisher (TMO) Keep the Earnings Surprise Streak Alive?

PerkinElmer

10X Genomics

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

3 Gene Sequencing Stocks With Potential to Gain in 2H22

Charles River Laboratories

While many companies worry about the global economy, Charles River and Thermo Fisher are optimistic.

These 2 Stocks May Be Recession-Proof

Quanterix

NATICK, Mass.--(BUSINESS WIRE)--Mercy BioAnalytics appoints Dawn Mattoon, PhD, as Chief Operating Officer to strengthen management team behind novel early cancer detection platform.

Mercy BioAnalytics Appoints Dawn Mattoon, PhD, as Chief Operating Officer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Applied Biosystems TaqPath Respiratory Viral Select Panel; a CE-IVD-marked molecular assay panel for detection of five common viruses, including those that cause the common cold, bronchiolitis, croup, influenza-like illnesses, and pneumonia. The molecular assay panel provides results in approximately three hours, testing for Adenovirus, Human Metapneumovirus, Rhino

Thermo Fisher Scientific Launches CE-IVD Marked TaqPath Respiratory Viral Select Panel

Vertex Pharmaceuticals

They're weathering the bear market better than many.

3 Unstoppable Growth Stocks To Buy in 2022 and Beyond

AutoZone

EPAM Systems

Exelon

Kroger

Pfizer

Progressive

Charles Schwab

T-Mobile US

After what can only be called a dismal first half, most investors are looking for some relief in the form of returns for the remainder of 2022.

Top 10 Q3 Ideas From Bank of America

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2022 before the market opens on Thursday, July 28, 2022, and will hold a conference call on the same day at 8:30 a.m. EDT. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (844) 200-6205 within the U.S. or (929) 526-1599 outside the U.S. The

Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 28, 2022

An industry-leading company looks past COVID-19 to future growth.

Why This Company Could See Long-Lasting Tailwinds Despite the Bear Market

Danaher

Two healthcare giants - Danaher and Thermo Fisher - are finally trading at a fair price. Over the last decades, both companies shown a great track record of excellent operations.

Danaher And Thermo Fisher: Buy These High-Quality Compounders At A Fair Price

Their prices are high enough that a split could be warranted.

Is a Stock Split Overdue for These 2 Stocks?

Home Depot

Pembina Pipeline

3 Growth Stocks That Raised Their Guidance This Year

Thermo Fisher's (TMO) RNA Polymerase III and EliA Rib-P blood tests are intended to diagnose systemic sclerosis and systemic lupus erythematosus.

Thermo Fisher's (TMO) Autoimmune Disease Test Gets FDA Nod

Thermo Fisher's (TMO) new deal with TransMIT will advance the use of the AP-SMALDI5 AF ion source with Orbitrap MS technology for spatial multi-omics applications.

Thermo Fisher (TMO) to Promote Mass Spectrometry Imaging

QIAGEN

LONDON--(BUSINESS WIRE)--Relation Therapeutics Closes $25 Million Seed Financing and Names David Roblin as CEO and Lindsay Edwards as CTO

Relation Therapeutics, the Active-Graph Machine Learning Drug Discovery Company, Names David Roblin as CEO and Lindsay Edwards as CTO

WILMINGTON, N.C.--(BUSINESS WIRE)--Thermo Fisher Scientific's PPD clinical research business has been named Clinical Research Company of the Year for the third consecutive year.

Thermo Fisher Scientific's Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific is offering an IVDR version of the Applied Biosystems QuantStudio 5 Dx Real-Time PCR System globally.

Thermo Fisher Scientific Updates Applied Biosystems QuantStudio 5 Dx Real-Time PCR System to Comply with IVDR Regulations

MINNEAPOLIS--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, is showcasing new instruments, workflows, software and industry collaborations that enable customers to generate new analytical insights and accelerate next generation vaccine and therapy development. The company will showcase these innovations during the 70th American Society for Mass Spectrometry (ASMS) Conference on Mass Spectrometry and Allied Topics, being held June 5-9, 2022, in th

Thermo Fisher Scientific Showcases Solutions for Accelerating Next Generation Vaccine and Therapy Research and Unlocking Deeper Analytical Insights

SAN JOSE, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Awards to top proteomics researchers for outstanding innovation and societal impact.

Thermo Fisher Scientific Recognizes Tandem Mass Tag Grant Award Winners

MINNEAPOLIS--(BUSINESS WIRE)--Co-marketing agreement with TransMIT allows for high spatial and high mass resolution MSI platform to study complex biological tissues.

Thermo Fisher Scientific Collaborates with TransMIT GmbH on a High-Performance Orbitrap Mass Spectrometry Imaging Platform

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today released its annual Corporate Social Responsibility (CSR) report. The report highlights the company's commitment to society and stakeholders providing detailed insight into the company's CSR progress and environmental, social and governance (ESG) efforts. “Our Mission to enable our customers to make the world healthier, cleaner and safer guides all of our actions,” said Marc N.

Thermo Fisher Scientific Releases Corporate Social Responsibility Report

Investors are optimistic about Thermo Fisher's (TMO) robust y/y revenue growth in the Analytical Instruments, and the Laboratory Products and Biopharma Services segments.

Here's Why You Should Retain Thermo Fisher (TMO) for Now

Thermo Fisher (TMO) witnesses core business strength across segments, end markets, and geographies.

News for Thermo Fisher Scientific Stock (TMO)